China's biotech surge isn't a surprise. It's the result of two decades of deliberate investment modeled on the same playbook that gave the U.S. four decades of biomedical leadership. 👉 John Stanford of Incubate on what the U.S. should do next: hubs.ly/Q04s8dMJ0 #Pharma #Biotech #PharmExec